Literature DB >> 27707957

Preliminary study on Emodin alleviating alpha-naphthylisothiocyanate-induced intrahepatic cholestasis by regulation of liver farnesoid X receptor pathway.

Yan Ding1, Xiao-Li Xiong2, Li-Shan Zhou2, Su-Qi Yan2, Huan Qin3, Hua-Rong Li4, Ling-Ling Zhang2, Peng Chen5, Cong Yao6, Zhi-Xia Jiang2, Lei Zhao7.   

Abstract

The aim of this study is to investigate Emodin on alleviating intrahepatic cholestasis by regulation of liver farnesoid X receptor (FXR) pathway. Cell and animal models of intrahepatic cholestatis were established. Biochemical tests and histomorphology were performed. The messenger RNA (mRNA) and protein expression of FXR, small heterodimer partner (SHP), uridine diphosphate glucuronosyltransferase 2 family polypeptide B4 (UGT2B4), and bile salt export pump (BSEP) was detected. As a result, compared with the model group, the serum levels of biochemical test were significantly lower in the Emodin group (P <0.01). The histopathological changes were remitted significantly by Emodin treatment. In the model group, the mRNA and protein expression of FXR, SHP, UGT2B4, and BSEP was significantly lower than in the normal group in cell models (P <0.05). With Emodin intervention, the expression of FXR, SHP, UGT2B4, and BSEP was notably increased (P <0.05). In conclusion, Emodin plays a protective role in intrahepatic cholestasis by promoting FXR signal pathways.
© The Author(s) 2016.

Entities:  

Keywords:  Emodin; farnesoid X receptor (FXR); intrahepatic cholestasis; α-naphthyl isothiocyanate

Mesh:

Substances:

Year:  2016        PMID: 27707957      PMCID: PMC5806847          DOI: 10.1177/0394632016672218

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  17 in total

Review 1.  Beyond bile acids: targeting Farnesoid X Receptor (FXR) with natural and synthetic ligands.

Authors:  Andrea Carotti; Maura Marinozzi; Chiara Custodi; Bruno Cerra; Roberto Pellicciari; Antimo Gioiello; Antonio Macchiarulo
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

Review 2.  Nuclear bile acid signaling through the farnesoid X receptor.

Authors:  Claire Mazuy; Audrey Helleboid; Bart Staels; Philippe Lefebvre
Journal:  Cell Mol Life Sci       Date:  2014-12-16       Impact factor: 9.261

3.  Activity of corilagin on post-parasiticide liver fibrosis in Schistosomiasis animal model.

Authors:  Y-F Huang; S-L Zhang; F Jin; D Cheng; Y-P Zhou; H-R Li; Z-M Tang; J Xue; W Cai; J-H Dong; L Zhao
Journal:  Int J Immunopathol Pharmacol       Date:  2013 Jan-Mar       Impact factor: 3.219

4.  Inhibition of farnesoid X receptor controls esophageal cancer cell growth in vitro and in nude mouse xenografts.

Authors:  Baoxiang Guan; Hao Li; Zhengduo Yang; Ashraful Hoque; Xiaochun Xu
Journal:  Cancer       Date:  2012-12-20       Impact factor: 6.860

5.  Protective effects of emodin and astragalus polysaccharides on chronic hepatic injury in rats.

Authors:  Shuang-suo Dang; Xin Zhang; Xiao-li Jia; Yan-an Cheng; Ping Song; En-qi Liu; Qian He; Zong-fang Li
Journal:  Chin Med J (Engl)       Date:  2008-06-05       Impact factor: 2.628

6.  Effect of Corilagin on the miR-21/smad7/ERK signaling pathway in a schistosomiasis-induced hepatic fibrosis mouse model.

Authors:  Fan Yang; Yao Wang; Jun Xue; Qian Ma; Juan Zhang; Yun-Fei Chen; Zhen-Zhong Shang; Quan-Qiang Li; Shu-Ling Zhang; Lei Zhao
Journal:  Parasitol Int       Date:  2016-03-02       Impact factor: 2.230

7.  Serum Metabolomic Profiling in a Rat Model Reveals Protective Function of Paeoniflorin Against ANIT Induced Cholestasis.

Authors:  Zhe Chen; Yun Zhu; Yanling Zhao; Xiao Ma; Ming Niu; Jiabo Wang; Haibin Su; Ruilin Wang; Jianyu Li; Liping Liu; Zhenman Wei; Qingguo Zhao; Hongge Chen; Xiaohe Xiao
Journal:  Phytother Res       Date:  2016-01-25       Impact factor: 5.878

Review 8.  Targeting FXR in cholestasis: hype or hope.

Authors:  Stefano Fiorucci; Eleonora Distrutti; Patrizia Ricci; Vittorio Giuliano; Annibale Donini; Franco Baldelli
Journal:  Expert Opin Ther Targets       Date:  2014-09-09       Impact factor: 6.902

9.  Pathological features of transplanted tumor established by CD133 positive TJ905 glioblastoma stem-like cells.

Authors:  Feng Jin; Ran Zhang; Song Feng; Chuan-Tao Yuan; Ren-Ya Zhang; Guang-Kui Han; Gen-Hua Li; Xi-Zhen Yu; Yang Liu; Ling-Sheng Kong; Shu-Ling Zhang; Lei Zhao
Journal:  Cancer Cell Int       Date:  2015-06-13       Impact factor: 5.722

Review 10.  Bile acid nuclear receptor FXR and digestive system diseases.

Authors:  Lili Ding; Li Yang; Zhengtao Wang; Wendong Huang
Journal:  Acta Pharm Sin B       Date:  2015-02-25       Impact factor: 11.413

View more
  5 in total

1.  Effects of corilagin on alleviating cholestasis via farnesoid X receptor-associated pathways in vitro and in vivo.

Authors:  Fan Yang; Yao Wang; Gang Li; Juan Xue; Zhi-Lin Chen; Feng Jin; Lei Luo; Xuan Zhou; Qian Ma; Xin Cai; Hua-Rong Li; Lei Zhao
Journal:  Br J Pharmacol       Date:  2018-01-25       Impact factor: 8.739

2.  Corilagin ameliorates the extreme inflammatory status in sepsis through TLR4 signaling pathways.

Authors:  Hua-Rong Li; Jie Liu; Shu-Ling Zhang; Tao Luo; Fei Wu; Ji-Hua Dong; Yuan-Jin Guo; Lei Zhao
Journal:  BMC Complement Altern Med       Date:  2017-01-05       Impact factor: 3.659

3.  Chlorogenic Acid Inhibits Liver Fibrosis by Blocking the miR-21-Regulated TGF-β1/Smad7 Signaling Pathway in Vitro and in Vivo.

Authors:  Fan Yang; Lei Luo; Zhi-De Zhu; Xuan Zhou; Yao Wang; Juan Xue; Juan Zhang; Xin Cai; Zhi-Lin Chen; Qian Ma; Yun-Fei Chen; Yu-Jie Wang; Ying-Ying Luo; Pan Liu; Lei Zhao
Journal:  Front Pharmacol       Date:  2017-12-19       Impact factor: 5.810

4.  Emodin Rescues Intrahepatic Cholestasis via Stimulating FXR/BSEP Pathway in Promoting the Canalicular Export of Accumulated Bile.

Authors:  Xiao-Li Xiong; Yan Ding; Zhi-Lin Chen; Yao Wang; Pan Liu; Huan Qin; Li-Shan Zhou; Ling-Ling Zhang; Juan Huang; Lei Zhao
Journal:  Front Pharmacol       Date:  2019-05-22       Impact factor: 5.810

5.  Emodin Attenuates Lipopolysaccharide-Induced Acute Liver Injury via Inhibiting the TLR4 Signaling Pathway in vitro and in vivo.

Authors:  Yan Ding; Pan Liu; Zhi-Lin Chen; Shao-Jun Zhang; You-Qin Wang; Xin Cai; Lei Luo; Xuan Zhou; Lei Zhao
Journal:  Front Pharmacol       Date:  2018-08-22       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.